Tengion, Inc. is an American development-stage regenerative medicine company founded in 2003 with financing from J&J Development Corporation, HealthCap and Oak Investment Partners, which is headquartered in Winston-Salem, North Carolina. Its goals are discovering, developing, manufacturing and commercializing a range of replacement organs and tissues, or neo-organs and neo-tissues, to address unmet medical needs in urologic, renal, gastrointestinal, and vascular diseases and disorders. The company creates these human neo-organs from a patient’s own cells or autologous cells, in conjunction with its Organ Regeneration Platform. The company declared Chapter 7 bankruptcy in December 2014, and it, along with its assets and tissue engineering samples, have been bought back by its creditors and former executives as of March 2015. The purchase was expedited, so that time-sensitive research can continue.

Based in Cologne, Germany, Sividon Diagnostics is a management buyout from Siemens Healthcare Diagnostics in Cologne. The aim of Sividon team of experienced scientists and managers was and still is, the quality of companion diagnostics in oncology to improve their products sustainably. So in the future treatment decisions could in cancer - especially breast cancer - will be further improved by an individualized, evidence-based diagnosis. In this way Sividon is also supported by an established international network of renowned experts. In addition to the many years of professional experience in molecular diagnostics, there are the extensive rights and to the year 2004 reaching back arrangements that characterize the team and Sividon.

Sync-Rx Ltd. develops trans-catheter cardiovascular interventions technology solutions. It focuses on cornory angioplasty and percutaneous valve replacement and repair. The company was founded by David Tolkowsky in 2007 and is headquartered in Netanya, Israel.

Genentech is a biotechnology company that discovers, develops, manufactures, and commercializes medicines to treat patients with serious or life-threatening medical conditions. It creates multiple products on the market and a development pipeline. The company became a member of the Roche Group in 2009. As part of their merger agreement, Roche and Genentech combined their pharmaceutical operations in the United States. Genentech’s South San Francisco campus now serves as the headquarters for Roche pharmaceutical operations in the United States. Genentech’s Research and Early Development section operates as an independent center within Roche. Genentech was founded in 1976 by [Robert Swanson](https://www.crunchbase.com/person/robert-a-swanson) and [Herbert Boyer](https://www.crunchbase.com/person/herbert-w-boyer). It is headquartered in South San Francisco, C.A.

Part of BioNTech SE, BioNTech Diagnostics GmbH is a company headquartered in Mainz, Germany, specializing in commercial physical and biological research. The firm was founded in 2009. Sierk P��tting is the current CEO of the company.\nThe company says this about itself: BioNTech Diagnostics is a fully-owned subsidiary company of BioNTech AG. The ISO 9001/13485 certified company has extensive product and service offerings ranging from biomarker discovery and validation through molecular screening assays, patient stratification and companion diagnostics to clinical monitoring, all to international regulatory standards. Early detection of diseases that have a high mortality rate and the appropriate selection of therapies are crucial for a successful treatment of patients. BioNTech Diagnostics�� mission is to provide new and innovative diagnostic tests to extend lives of patients, improve their quality of life and support the use of appropriate therapy for each individual patient.

Qingdao Reside Medical Laboratory Co., Ltd., established on 2018-09-07, Business scope includes licensed projects:Drug Clinical Trial Services;medical service;Collection and supply of raw plasma;Internet hospital services relying on physical hospitals;Inspection and testing service;Production of Class II Medical Devices;Production of Class III Medical Devices;Class III medical device business.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments,The specific business items are subject to the approval documents or licenses of relevant departments)General project:Natural science research and experimental development;Engineering and Technology Research and Experimental Development;Medical Research and Experimental Development;Information Technology Consulting Services;R&D and application of cell technology;Production of Class I Medical Devices;Sales of Class II Medical Devices;Sales of Class I Medical Devices;Technical Services,technology development,technical consulting,Technology Exchange,technology transfer,Technology Promotion;Small and mini bus rental business service.(Except for projects subject to approval by law,Carry out business activities independently in accordance with the law with a business license)

F. Hoffmann-La Roche Ltd. manufactures pharmaceutical products. It offers pharmaceutical drugs, pharmaceutical instruments, and diagnostics solutions. The company was founded by Fritz Hoffmann-La Roche on October 1, 1896 and is headquartered in Basel, Switzerland.

Vysera Biomedical Ltd. develops medical devices and therapies. The firm's products can be delivered directly to target sites on the inner surface of the gastrointestinal tract (GI) via conventional, minimally invasive techniques. It is developed to address the significant unmet need for gastrointestinal reflux control. The company was founded by Donal Devery in 2005 and is headquartered in Galway, Ireland.

Nanjing Kaifu Biotechnology Co., Ltd., established on 2019-03-26, Business scope includes biotechnology,Medical technology research and development,technology transfer,Technical Services,technical consulting;R&D and sales of medical devices;Development and sales of diagnostic kits.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments)

Massachusetts General Hospital was established to provide care to Boston's sick, regardless of socioeconomic status—an innovative idea in 1811. In the words of their founder, John Warren, MD, “When in distress, every man becomes their neighbor.” They subsequently became the first teaching hospital for Harvard University’s new medical school and have been redefining excellence in healthcare ever since. They have remained at the forefront of medicine by fostering a culture of collaboration, pushing the boundaries of medical research, educating the brightest medical minds and maintaining an unwavering commitment to the diverse community they were created to serve. They believe that because of diversity they excel, through inclusion they respect their community, and with a keen focus on equity they serve, heal, educate and innovate at the highest levels. Their first priority is the well-being of their patients—near and far. As a team they are able to maintain a singular focus on providing the highest quality, most compassionate care to each and every patient.

Coloplast A/S develops, manufactures, and markets medical products. It operates through the following segments: Chronic Care, Interventional Urology and Wound & Skin Care. The Chronic Care segment covers the sale of ostomy care products and continence care products. The Interventional Urology segment covers the sale of urological products, including disposable products. The Wound & Skin Care segment covers the sale of wound and skin care products. The company was founded by Aage Louis-Hansen and Johanne Louise-Hansen in 1954 and is headquartered in Humlebaek, Denmark.

Inbiomotion is focused on the development and commercialization of a biomarker that predicts metastasis to improve patients' quality of life by personalizing the adjuvant treatment of early stage breast cancer. Founded in 2010 by Dr. Roger Gomis, it is a spin-off of IRB Barcelona and ICREA research institutions. Inbiomotion's unique diagnostic assay is based on a highly selective single gene biomarker. Data generated thus far suggests such biomarker can identify early stage breast cancer patients that will benefit from bisphosphonate adjuvant treatment improving their overall and invasive disease free survival. It can further predict at an early stage a patient's risk of metastases relapse from primary tumors. The selectivity of the lead biomarker has the potential to advance the clinical standard of care using personalized medicine.

Shenyou Genome Research Institute (Nanjing) Co., Ltd., established on 2018-04-19, The scope of business includes the research and development of gene technology and its technology transfer and consulting services;health management;Health Advisory;business management;Business Management Consulting;Technology development in the field of biomedical technology,technology transfer,Technical Services,technical consulting;electronic product,Instrumentation,Chemical product sales;Self-operated and agent import and export business of various commodities and technologies.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments)(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments) licensed items:Production of Class II Medical Devices;Production of Class III Medical Devices;Class III medical device business(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments,Specific business projects are subject to approval results) General project:Production of Class I Medical Devices;Sales of Class I Medical Devices;Sales of Class II Medical Devices(Except for projects subject to approval by law,Carry out business activities independently in accordance with the law with a business license)

Zhiji Future (Chengdu) Biotechnology Co., Ltd., established on 2017-05-02, Business scope includes genetic testing;Research and development of genetic testing technology;Technical extension services;Technology intermediary service;Online Trade Agent;software development;Information Technology Consulting Services;Internet information service;Health Consulting Services;Medical device research and development;Medical device production(Restrict branches to operate in industrial parks);Sales:medical instruments,food.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments).

Shenzhen Shengjing Gene Biotechnology Co., Ltd., established on 2017-10-11, Business scope includes general business items:Biotechnology R&D,technology transfer,Technical Services,technical consulting;Technology development in medical technology,technology transfer,Technical Services,technical consulting;Leasing of medical equipment;Provide logistics management services for hospitals;translation service;Health Advisory,Health Management Services,Biopharmaceutical R&D and Services;Domestic Trade(Does not contain franchise,Exclusive control,Monopoly).,The licensing program is:Pre-packaged food,Bulk food research and development and sales,R&D and sales of health care products.Sales of infant formula milk powder;Sales of infant formula;Catering Services;Hot food production and sales,Frozen food production and sales,Raw food production and sales,Manufacture and sales of cakes,Production and sale of homemade drinks.

Anhui Yuntai Biotechnology Co., Ltd., established on 2016-05-23, The scope of business includes technology research and development in the field of biological science and technology,technical consulting,Technical Services,technology transfer,medical instruments,Laboratory Equipment Sales.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments)